Abstract OBJECTIVE: To study the efficacy and safety of 125I particle implantation in the treatment of rhabdomysarcoma (RMS) of the head and neck in children. METHODS: Eight children (four males and four females) with RMS of the head and neck received 125I particle implantation targeted to the primary lesion area. The primary lesions were noted in eyelids or eyes in two children, in the orbit in four children, and in the nasal cavity or nasal wing in two children. Treatment outcomes and side effects were observed. RESULTS: The follow-up visits averaged 45±17 months (median 43 months) in the eight children receiving 125I particle implantation. Five children achieved a complete remission, 2 children achieved a complete remission and 1 child died. The total survival rate was 88% in the 8 children. Local pigmentation was observed in all eight children (100%). Nubecula (one case), eyeball pain (one case), serious blurred vision (one case), cornea ulcer and blindness (one case) and bleeding of the nasal cavity (one case) were also observed. Except for nubecula and blindness, these side effects were improved by symptomatic treatment. CONCLUSIONS: 125I particle implantation appears to be effective in the treatment of RMS of the head and neck in children. Most treatment-related side effects can be improved by symptomatic treatment.
ZHANG Yi,GUO Fang,ZHANG Wei-Ling et al. Clinical application of 125I particle implantation in children with rhabdomysarcoma of the head and neck[J]. 中国当代儿科杂志, 2012, 14(06): 437-440.
ZHANG Yi,GUO Fang,ZHANG Wei-Ling et al. Clinical application of 125I particle implantation in children with rhabdomysarcoma of the head and neck[J]. CJCP, 2012, 14(06): 437-440.
［3］Rodeberg D, Pai das C. Childhood rhabdomyosarcoma［J］. Semin Pediatr Surg, 2006, 15(1): 57-62.
［4］Trahair T, Andrews L, Cohn RJ. Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma［J］. Pediatr Blood Cancer, 2007, 48(3): 345-348.
［5］Schuck A, Mattke AC, Schmidt B, Kun DS, Harms D, Knietig R, et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumours: is radiotherapy necessary［J］ J Clin Oncol, 2004, 22（1）: 143-149.
［6］Vinswanathan AN, Grier HE, Litman HJ, Perez-Atayde A, Tarbell NJ, Neuberg D, et al. Outcome for children with group Ⅲrhabdomyosarcoma treated with or without radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2004, 58(4): 1208-1214.
［7］Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A, Pappo AS, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group［J］. Pediatr Blood Cancer, 2011, 57(1): 76-83.
［10］Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, et al. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group［J］. Clin Cancer Res, 2010, 16(2): 750-754
